<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002337</url>
  </required_header>
  <id_info>
    <org_study_id>234B</org_study_id>
    <secondary_id>22-93-252</secondary_id>
    <nct_id>NCT00002337</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease</brief_title>
  <official_title>A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka America Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with&#xD;
      advanced HIV disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least&#xD;
      seven patients at a given dose level must have completed 4 weeks of treatment before dose is&#xD;
      escalated in subsequent patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>56</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesnarinone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Chemoprophylaxis for Pneumocystis carinii, candida, mycobacteria, and other&#xD;
             opportunistic infections.&#xD;
&#xD;
          -  Acyclovir for up to 14 days for acute herpes outbreaks.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  CD4 count 50 - 300 cells/mm3.&#xD;
&#xD;
          -  No active opportunistic infections.&#xD;
&#xD;
          -  No fever, diarrhea, or Herpes zoster.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Clinically significant current cardiac disease, including patients who exhibit long&#xD;
             QTC syndrome on EKG screening and who have an abnormal cardiothoracic ratio on chest&#xD;
             x-ray at baseline.&#xD;
&#xD;
          -  Active malignancy (other than cutaneous Kaposi's sarcoma or cutaneous basal cell&#xD;
             carcinoma or in situ carcinoma of the cervix).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral agents, including ddI, ddC, AZT, and d4T.&#xD;
&#xD;
          -  Immunosuppressive agents.&#xD;
&#xD;
          -  Investigational HIV drugs/therapies including vaccines.&#xD;
&#xD;
          -  Interferon or other immunomodulating agents.&#xD;
&#xD;
          -  Corticosteroids (other than topical).&#xD;
&#xD;
          -  Hematopoietins.&#xD;
&#xD;
          -  Megestrol acetate.&#xD;
&#xD;
          -  Agents known to cause neutropenia.&#xD;
&#xD;
          -  Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg&#xD;
             sulfamethoxazole thrice weekly.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Prior history of cardiac disease.&#xD;
&#xD;
          -  History of agranulocytosis or severe (grade 3 or worse) drug-induced neutropenia or&#xD;
             documented abnormalities in granulocyte function.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  AZT, ddI, ddC, d4T, or other nucleoside analog antiretroviral therapy within 14 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Prior cytotoxic chemotherapy.&#xD;
&#xD;
          -  Acyclovir for herpes prophylaxis within 48 hours prior to study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days prior to study entry:&#xD;
&#xD;
          -  Erythropoietin, transfusion, or blood product use.&#xD;
&#xD;
          -  Radiation therapy (including electron beam irradiation). Active use of illicit drugs&#xD;
             (specifically cocaine, amyl nitrate, heroin, and other cardioactive agents).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>vesnarinone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vesnarinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

